厦门迈瑞思邦生物科技

Xiamen Myrisborn Biotechnology is a clinical-stage biopharmaceutical company focused on developing innovative peptide therapeutics for metabolic and endocrine disorders. The company utilizes a proprietary peptide drug discovery platform to design multi-target agonists, such as dual and triple receptor agonists targeting GLP-1, GIP, and glucagon pathways. Their lead candidate, MRB-001, is a long-acting GLP-1/GIP dual receptor agonist currently in Phase 1 clinical trials for obesity and type 2 diabetes. Myrisborn aims to address the global challenge of metabolic diseases by improving the efficacy, safety, and dosing convenience of peptide-based treatments. Headquartered in Xiamen, China, the company is backed by prominent investors including Qiming Venture Partners and Sequoia China.